SAB Biotherapeutics, Inc., (SABS): Price and Financial Metrics

SAB Biotherapeutics, Inc., (SABS): $1.76

0.03 (-1.68%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

Add SABS to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#112 of 303

in industry

SABS Price/Volume Stats

Current price $1.76 52-week high $5.01
Prev. close $1.79 52-week low $1.00
Day low $1.72 Volume 8,600
Day high $1.82 Avg. volume 80,563
50-day MA $1.71 Dividend yield N/A
200-day MA $2.47 Market Cap 16.35M

SABS Stock Price Chart Interactive Chart >


SAB Biotherapeutics, Inc., (SABS) Company Bio


SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic for the treatment of COVID-19 advancing as part of the NIH's ACTIV-2 protocol; and SAB-176, a fully-human polyclonal antibody therapeutic candidate designed to bind to type A and B viruses. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection; and SAB-181 for immune globulin (IgG) mediated diseases. It focuses on infectious diseases, such as COVID-19 and influenza, immune system disorders comprising type 1 diabetes, organ transplantation, and cancer. The company was founded in 2014 and is based in Miami Beach, Florida.


SABS Latest News Stream


Event/Time News Detail
Loading, please wait...

SABS Latest Social Stream


Loading social stream, please wait...

View Full SABS Social Stream

SABS Price Returns

1-mo -2.76%
3-mo 15.03%
6-mo -57.89%
1-year -40.54%
3-year -88.27%
5-year N/A
YTD -53.61%
2024 -44.81%
2023 16.55%
2022 -92.45%
2021 N/A
2020 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!